AC Immune SA (ACIU)
- Previous Close
2.4200 - Open
2.4500 - Bid 2.3300 x 100
- Ask 2.4500 x 100
- Day's Range
2.3700 - 2.5100 - 52 Week Range
1.7800 - 5.1400 - Volume
189,450 - Avg. Volume
182,727 - Market Cap (intraday)
235.379M - Beta (5Y Monthly) 1.01
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7000 - Earnings Date Apr 26, 2024 - Apr 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.49
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It is developing Crenezumab, a humanized, conformation-specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome-related AD; ACI-7104.056, to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it is developing diagnostic programs, consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD and NeuroOrphan Tauopathies. Additionally, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
www.acimmune.comRecent News: ACIU
Performance Overview: ACIU
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACIU
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACIU
Valuation Measures
Market Cap
238.35M
Enterprise Value
129.09M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.53
Price/Book (mrq)
1.35
Enterprise Value/Revenue
8.72
Enterprise Value/EBITDA
-2.49
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-18.18%
Return on Equity (ttm)
-32.90%
Revenue (ttm)
14.8M
Net Income Avi to Common (ttm)
-54.23M
Diluted EPS (ttm)
-0.7000
Balance Sheet and Cash Flow
Total Cash (mrq)
103.05M
Total Debt/Equity (mrq)
2.18%
Levered Free Cash Flow (ttm)
-42.11M